Thursday, October 6, 2022 | Back issues
Courthouse News Service Courthouse News Service

Ariad Pharmaceuticals

BOSTON - Ariad Pharmaceuticals boosted its stock price by failing to disclose problems with a cancer drug, and the share price dropped by nearly two-thirds when the truth came out, shareholders claim in Federal Court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.